{"url_path":"/sec/slxnw/8-k/2026-05-14/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/2022416/0001178913-26-002705-index.html","accession_number":"0001178913-26-002705","cik":"0002022416","ticker":"SLXN","issuer_name":"Silexion Therapeutics Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/2022416/0001178913-26-002705-index.html","primary_entity_key":"0002022416","primary_entity_name":"Silexion Therapeutics Corp"},"word_count":73,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits\n\n \n\n(d) Exhibits\n\n \n\n \n\n[99.1](exhibit_99-1.htm)\n\n[Press Release dated May\n14, 2026](exhibit_99-1.htm)\n\n \n\n \n\n104\n\nCover Page Interactive Data File (formatted in Inline XBRL)\n\n \n\nSIGNATURE\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to\nbe signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\nSILEXION THERAPEUTICS CORP\n\n \n\n \n\nDate: May 14, 2026\n\n/s/ Ilan Hadar\n\n \n\nName:\n\nIlan Hadar\n\n \n\nTitle:\n\nChief Executive Officer"}